GLP1R and type 2 diabetes mellitus: According to the American Diabetes Association (ADA) 2022 guidelines, there is evidence supporting significant cardiovascular benefits of four FDA-approved GLP-1 RAs (liraglutide, albiglutide, semaglutide, and dulaglutide) and three FDA-approved SGLT2 inhibitors (empagliflozin, canagliflozin, and dapagliflozin), with lesser benefits seen with ertugliflozin, for patients with T2D and high risk of ASCVD (AD A, 2022).